CLGN
CollPlant Biotechnologies Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$4.13
+0.49%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.19
From 52W high−81.56%
Volume15115.00
Market cap$11.89M
P/E (TTM)—
P/S (TTM)37.4x
Div yield—
Key dataNov 4, 2026
Open
$4.19
From 52W high
−81.56%
Volume
15115.00
Market cap
$11.89M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.0x
P/E (TTM)
—
RSI (14)
60.2
MomentumView details →
1D Return
+0.49%
YTD Return
−68.75%
SummaryUpdated Jun 1, 2026
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) is an Israeli biotechnology company founded in 2004 and headquartered in Rehovot, Israel. The company went public on NASDAQ in January 2018. CollPlant specializes in regenerative and aesthetic medicine, focusing on developing innovative medical products based on recombinant human collagen produced through proprietary plant-based genetic engineering technology. The company operates in the rapidly evolving biotechnology sector, developing solutions for tissue regeneration, wound care, and aesthetic medicine applications.
Similar companies
Latest newsMore news →
CollPlant Biotechnologies Ltd announced that its board approved a proposal to change the company’s name to CollPlant Biotechnologies Ltd6h agoLightSolver secured a paid collaboration with the Israel Ministry of Defense to develop photonic computing technology.6d agoLightSolver, a subsidiary of CollPlant Biotechnologies, filed a U.S. provisional patent application with the USPTO expanding its all-optical, laser-based photonic computing platform to advanced scientific and engineering simulations.29d ago